Targets › GP128
1 program from 1 company in 1 trial: 1 Phase 1; Oncology.
Open in Phaseline: the race on GP128, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Amal Therapeutics | ATP128 Self-adjuvanted chimeric recombinant protein vaccine targeting GP128 antigen | GP128 | Phase 1 | Colorectal Cancer | – |
Colorectal Cancer (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.